Anti Aging Breakthroughs 2025

Superintelligence is a newsletter to guide you in surviving & thriving in the age of Al.Founded by & written daily by Kim we cover all of the latest Al news &product releases, in addition to deep dives in:

A newsletter co-hosted by the Wyss Institute at Harvard University, focusing on the intersection of AI, biology, and healthcare to transform medicine, with emphasis on AI-driven drug discovery and accelerating life-saving therapies.

Daily insights into health care innovations, including AI's role in drug discovery, repurposing existing drugs for rare diseases, and accelerating treatments for conditions like idiopathic pulmonary fibrosis and ALS.

Breaking news and breakthroughs on AI applications in healthcare, covering precision medicine, AI-discovered drugs for cancer and neurological disorders, and accelerated timelines in psychiatric drug design.

UCLA researchers developed PP405, a topical molecule that inhibits the SCUBE3 protein to 'wake up' dormant hair follicle stem cells, promoting regrowth. Phase 1 trials showed safety and follicle activation in humans within a week; Phase 3 starts in 2026. Effective in mice for full reversal, with potential to regrow hair on scarred scalps.

Absci's AI-generated drug ABS-201 targets the telogen (shedding) phase directly, bypassing initial hair loss from minoxidil. It reactivates follicles and repigments hair, with preclinical data showing reversal in balding models. Phase 1 human trials launched mid-2025; could hit market by 2028.

Eirion Therapeutics' ET-02 flips a metabolic pathway in follicle cells, outperforming existing drugs in Phase 1 (N=24) with 2x hair density gains. Prevents greying too; Phase 2 (N=150) starts Q1 2026. Targets 80M US sufferers, with potential for prevention.

UC Irvine's injectable AMP-303 sends a 'print signal' to dormant follicles, yielding 15%+ increase in thick hair after one treatment (vs. placebo). Effects last 150+ days; addresses recent and long-term loss. Phase 2 trials ongoing, with human data from 2025 study.

Madrid's San Carlos Hospital combined fat-derived stem cells with ATP (energy molecule) to reverse pattern baldness in mice males regrew fur, 90% females fully revived. Human trials planned for 2026; focuses on follicle energy dysfunction.

UVA discovered latent stem cells persist in bald scalps; depleting them halts growth, but reactivating could repopulate follicles. Lab tests on human samples show migration potential for regrowth; early-stage, but paradigm-shifting for scarring alopecia.

MIT's microneedle patch delivers drugs to restore immune privilege in follicles, reversing alopecia areata in mice (full regrowth). Human trials via Phase 1 in 2025; targets autoimmune-driven loss, not just pattern baldness.